• Consensus Rating: Buy
  • Consensus Price Target: $47.50
  • Forecasted Upside: 46.15%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$32.50
▲ +0.72 (2.27%)

This chart shows the closing price for XNCR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xencor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XNCR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XNCR

Analyst Price Target is $47.50
▲ +46.15% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $47.50, with a high forecast of $58.00 and a low forecast of $36.00. The average price target represents a 46.15% upside from the last price of $32.50.

This chart shows the closing price for XNCR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in Xencor. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/7/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/5/2021
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2022
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2022
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2022CowenInitiated CoverageOutperformLow
12/6/2022CowenInitiated CoverageOutperformLow
11/9/2022Canaccord Genuity GroupLower Target$50.00 ➝ $48.00Low
11/8/2022Royal Bank of CanadaLower TargetOutperform$40.00 ➝ $36.00Low
10/13/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$58.00Low
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$37.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$50.00N/A
5/23/2022Piper SandlerLower TargetOverweight$66.00 ➝ $42.00High
5/6/2022Piper SandlerLower Target$71.00 ➝ $66.00Low
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
2/24/2022HC WainwrightLower TargetBuy$61.00 ➝ $55.00High
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$54.00Medium
1/21/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$60.00High
12/15/2021HC WainwrightInitiated CoverageBuy$61.00High
11/9/2021BTIG ResearchReiterated RatingBuyHigh
11/9/2021Piper SandlerLower TargetOverweight$75.00 ➝ $71.00High
10/5/2021Piper SandlerBoost TargetOverweight$63.00 ➝ $75.00High
9/28/2021GuggenheimLower TargetBuy$57.00 ➝ $50.00High
8/5/2021SVB LeerinkLower TargetOutperform$57.00 ➝ $53.00Low
5/9/2021SVB LeerinkReiterated RatingBuy$57.00High
5/6/2021WedbushLower TargetOutperform$52.00 ➝ $47.00Medium
2/24/2021SVB LeerinkReiterated RatingOutperformHigh
2/24/2021Royal Bank of CanadaBoost TargetOutperform$48.00 ➝ $59.00High
2/24/2021BarclaysBoost TargetUnderweight$31.00 ➝ $34.00Low
2/24/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$58.00Low
11/16/2020Cantor FitzgeraldBoost TargetOverweight$40.00 ➝ $56.00Low
11/6/2020SVB LeerinkBoost TargetOutperform$42.00 ➝ $46.00High
9/8/2020SVB LeerinkLower TargetOutperform$42.00 ➝ $39.00High
8/5/2020SVB LeerinkLower TargetOutperform$44.00 ➝ $42.00Low
8/5/2020MizuhoReiterated RatingBuyLow
7/21/2020MizuhoReiterated RatingBuy$52.00Low
7/8/2020Piper SandlerReiterated RatingBuy$46.00Medium
7/8/2020MizuhoReiterated RatingBuy$52.00Medium
5/10/2020NomuraReiterated RatingSell$21.00High
5/7/2020MizuhoReiterated RatingBuy$52.00High
3/4/2020BarclaysInitiated CoverageUnderweight$28.00High
2/25/2020GuggenheimUpgradeNeutral ➝ Buy$43.00High
2/17/2020MizuhoReiterated RatingBuy$52.00Medium
1/30/2020Royal Bank of CanadaInitiated CoverageOutperform$44.00High
12/18/2019MizuhoReiterated RatingBuy$52.00Medium
11/20/2019GuggenheimInitiated CoverageHoldHigh
11/6/2019SVB LeerinkLower TargetOutperform$52.00 ➝ $44.00Medium
11/5/2019MizuhoReiterated RatingBuyMedium
8/8/2019Nomura SecuritiesReiterated RatingSell$21.00Low
8/7/2019SVB LeerinkSet TargetBuy$52.00Low
8/7/2019Raymond JamesReiterated RatingOutperform ➝ Market PerformHigh
8/7/2019WedbushBoost TargetOutperform$43.00 ➝ $54.00High
8/7/2019GuggenheimDowngradeBuy ➝ NeutralHigh
7/8/2019Piper Jaffray CompaniesBoost TargetOverweight$56.00 ➝ $67.00Low
7/1/2019MizuhoReiterated RatingBuy$52.00High
6/12/2019MizuhoInitiated CoverageBuy ➝ Buy$52.00Medium
5/12/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
4/12/2019GuggenheimInitiated CoverageBuy$42.00Low
4/2/2019Cantor FitzgeraldReiterated RatingBuy$40.00Low
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$45.00Low
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$27.85High
2/26/2019Piper Jaffray CompaniesBoost TargetOverweight$56.00Medium
2/22/2019Nomura SecuritiesDowngradeNeutral ➝ Reduce$28.00 ➝ $21.00High
2/5/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
12/7/2018WedbushBoost TargetOutperform ➝ Outperform$42.00 ➝ $44.00Medium
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/6/2018Cantor FitzgeraldReiterated RatingBuy$40.00High
10/8/2018WedbushReiterated RatingOutperform$42.00Low
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$56.00High
8/7/2018Piper Jaffray CompaniesReiterated RatingTop Pick ➝ OverweightHigh
6/7/2018BTIG ResearchInitiated CoverageBuy$56.00Low
4/5/2018Nomura SecuritiesLower TargetNeutral$28.00Low
3/29/2018Cantor FitzgeraldReiterated RatingBuy$37.00Low
3/28/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$36.00Low
3/19/2018WedbushBoost TargetOutperform$38.00 ➝ $39.00Low
3/1/2018Cantor FitzgeraldReiterated RatingOverweight$37.00High
2/22/2018Cantor FitzgeraldInitiated CoverageBuy$33.00Low
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/2/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
9/1/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/1/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/31/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/30/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/30/2022
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
1/29/2023

Current Sentiment

  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Xencor logo
Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Read More

Today's Range

Now: $32.50
Low: $31.82
High: $32.72

50 Day Range

MA: $28.14
Low: $24.79
High: $32.59

52 Week Range

Now: $32.50
Low: $19.35
High: $35.92

Volume

259,418 shs

Average Volume

326,992 shs

Market Capitalization

$1.95 billion

P/E Ratio

67.71

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Xencor?

The following sell-side analysts have issued reports on Xencor in the last year: BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, and TheStreet.
View the latest analyst ratings for XNCR.

What is the current price target for Xencor?

8 Wall Street analysts have set twelve-month price targets for Xencor in the last year. Their average twelve-month price target is $47.50, suggesting a possible upside of 46.2%. Raymond James has the highest price target set, predicting XNCR will reach $58.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $36.00 for Xencor in the next year.
View the latest price targets for XNCR.

What is the current consensus analyst rating for Xencor?

Xencor currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XNCR will outperform the market and that investors should add to their positions of Xencor.
View the latest ratings for XNCR.

What other companies compete with Xencor?

How do I contact Xencor's investor relations team?

Xencor's physical mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company's listed phone number is (626) 305-5900 and its investor relations email address is [email protected] The official website for Xencor is www.xencor.com. Learn More about contacing Xencor investor relations.